☆ 4.6 Article

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Hematology

High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature

Bhaskar C. Kolla et al.

Summary: Following the 2017 ELN guidelines, changing consolidation therapy from high-dose cytarabine to intermediate-dose cytarabine in young, favourable-risk AML patients led to a significantly higher risk of relapse with IDAC compared to HIDAC.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Hematology

Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients

Kittisak Tangchitpianvit et al.

Summary: The study compared the efficacy of intermediate-dose cytarabine (IDAC) and high-dose cytarabine (HiDAC) as consolidation chemotherapy for acute myeloid leukemia (AML), finding no significant difference in one-year relapse-free survival rate and overall survival rate between the two groups. The duration of grade 3-4 thrombocytopenia was significantly shorter in the IDAC group. It is important to weigh the benefits and side effects when choosing between different treatment options.

HEMATOLOGY (2021)

添加到收藏夹

Review Hematology

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Hartmut Doehner et al.

BLOOD (2017)

添加到收藏夹

Letter Hematology

Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis

Kinkini N. Magina et al.

BLOOD (2017)

添加到收藏夹

Article Hematology

Sense and nonsense of high-dose cytarabine for acute myeloid leukemia

Bob Lowenberg

BLOOD (2013)

添加到收藏夹

Article Oncology

High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial

Markus Schaich et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Hematology

A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study

Shuichi Miyawaki et al.

BLOOD (2011)

添加到收藏夹

Article Hematology

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study

Xavier Thomas et al.

BLOOD (2011)

添加到收藏夹

Article Hematology

Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria

Raphael Itzykson et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)

添加到收藏夹

Article Oncology

Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study

Markus Schaich et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Medicine, General & Internal

Cytarabine Dose for Acute Myeloid Leukemia

Bob Löwenberg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Oncology

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine:: A Cancer and Leukemia Group B study

Andreas Neubauer et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.